Multi-component intervention for Lipidemia

Waitlist Available · 18+ · All Sexes · Durham, NC

This study is evaluating whether a nurse intervention may help improve the uptake of cardiovascular disease preventive therapies among people living with HIV.

See full description

About the trial for Lipidemia

Eligible Conditions
Cardiovascular Diseases · Hypertension · Hyperlipidemias · Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)

Treatment Groups

This trial involves 2 different treatments. Multi-component Intervention is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Multi-component intervention
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
General prevention education


This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Age ≥18 years
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 12 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 12 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Multi-component intervention will improve 1 primary outcome, 1 secondary outcome, and 2 other outcomes in patients with Lipidemia. Measurement will happen over the course of 12 months.

% of subjects in each hyperlipidemia cascade category
Ordinal 4-level variable across 4 time points (0, 4, 8, and 12 months). The hypercholesterolemia cascade tool consists of ordered categories as follows: 1=undiagnosed hyperlipidemia; 2=hyperlipidemia diagnosed; 3=hyperlipidemia diagnosed and appropriately managed; 4=hyperlipidemia diagnosed, appropriately managed, and non-HDL cholesterol target achieved.
Systolic blood pressure
Repeated measures across 4 time points (0, 4, 8, and 12 months)
% of subjects in each hypertension cascade category
Ordinal 4-level variable across 4 time points (0, 4, 8, and 12 months). The hypertension cascade tool consists of mutually exclusive categories as follows: 1=undiagnosed hypertension; 2=hypertension diagnosed; 3=hypertension diagnosed and appropriately managed; 4=hypertension diagnosed, appropriately managed, and blood pressure target achieved.
Non high density lipoprotein (Non-HDL) cholesterol
Repeated measures across 4 time points (0, 4, 8, and 12 months)

Who is running the study

Principal Investigator
C. T. L.
Prof. Chris Todd Longenecker, Associate Professor of Medicine
University of Washington

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of lipidemia?

The signs of lipidemia are easy to detect. Among people with abnormal cholesterol levels, there is an association between abnormal blood triglyceride levels and LDL cholesterol.

Anonymous Patient Answer

Can lipidemia be cured?

Lipidemia treatment could have a positive impact on metabolic disorders like obesity, impaired glucose tolerance and metabolic syndrome. But the results of our meta-analysis indicated that the lipid lowering effect on total or cardiovascular events could have no significant influence.

Anonymous Patient Answer

What is lipidemia?

Recent findings show the relationship between lipoprotein subclasses and coronary heart disease risk. High levels of low density lipoproteins or low density lipoprotein-cholesterol are also correlated with increased risk of coronary heart disease, suggesting that hypercholesterolemia in a general population is a significant risk factor for heart disease.

Anonymous Patient Answer

How many people get lipidemia a year in the United States?

About 8% of American adults have high blood cholesterol. However, only about 0.3% of US adults have elevated blood cholesterol. The actual number of those affected by elevated blood cholesterol cannot be estimated accurately based on those who have cholesterol testing and are known to receive care or on those who test negative for high cholesterol. As with most diseases, the number of people with hypercholesterolemia who are unaffected is much higher. It is also important to note that the overwhelming majority of those with elevated cholesterol do not suffer any detectable heart disease.

Anonymous Patient Answer

What are common treatments for lipidemia?

It was hard to identify common treatments for lipidemia because they are rare in clinical practice. The main treatment prescribed for lipidemia is HMGCoA-reducing drugs. Treatment of hypertriglyceridemias is not so common, however, often due to the high cost. It was concluded that patients should be targeted for more frequent follow-up since the main objectives of treatment are to make sure the cholesterol level is kept normal and to manage the comorbidities.

Anonymous Patient Answer

What causes lipidemia?

It has been postulated that dietary factors play an important role with hyperlipidemia being related to the consumption of cholesterol-enriched foods, high fat diets, and to a high intake of trans fats.

Anonymous Patient Answer

What is the primary cause of lipidemia?

[The major cause of familial hypercholesterolemia, familial combined hyperlipidemia, and familial homozygous hypercholesterolemia are LDL (R1447Q in LDLR gene)(R1447H in PCSK9 gene) mutations.[7] A significant part of familial hypercholesterolemia and familial combined hyperlipidemia are due to heterozygous or compound heterozygous mutations in LDLR gene (R1447Q in LDLR gene) and PCSK9 gene(R1447H in PCSK9 gene, respectively). The most common cause of familial combined hyperlipidemia is R1447Q mutation in LDLR gene.

Anonymous Patient Answer

How does multi-component intervention work?

Although the components of a multi-model intervention have been studied, the effectiveness and cost of such interventions to prevent cardiovascular disease in low-income families with Type 2 diabetes are not well understood. A randomized controlled trial is justified for determining the effectiveness of such multi-component interventions for this population, as well as for evaluating the cost-effectiveness of such interventions.

Anonymous Patient Answer

Does lipidemia run in families?

Based on results from this study, familial influences appear to be considerable for the risk of lipid disturbances. A more precise definition of familial influences may be necessary in determining the role if any of the risk factors is of genetic origin.

Anonymous Patient Answer

What is the latest research for lipidemia?

Hyperlipidemia, particularly raised TG, may be an important risk factor for CVD. High levels of total cholesterol in combination with increasing levels of LDL and lowering levels of HDL cholesterol can increase the risk of atherosclerosis, suggesting that these lipid levels may be independent risk factors for developing CVD. In addition to blood tests, researchers believe that a comprehensive evaluation of lipid levels might be important to prevent and manage these disorders.

Anonymous Patient Answer

Is multi-component intervention typically used in combination with any other treatments?

There were some differences in the use of multi-component interventions; the use of a combination was not uncommon in combination therapy. Additional trials are needed to establish the effectiveness of multi-component treatments versus single-component treatments in CHD prevention and primary/secondary prevention of CHD events and CHD complications with particular reference to secondary prevention of non-fatal stroke or myocardial infarction.

Anonymous Patient Answer

Has multi-component intervention proven to be more effective than a placebo?

A comprehensive approach combining lifestyle and drug intervention significantly reduced hsCRP levels, and this effect was more pronounced among patients with high baseline CRP levels. These data suggest that an integrated medical and psychological intervention targeting atherogenic risk factors may result in considerable beneficial effects.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Lipidemia by sharing your contact details with the study coordinator.